The pharmaceutical marketplace operates at the precise intersection of rapid clinical innovation, rigid federal regulatory mandates, and the high-stakes pursuit of therapeutic efficacy. Within this complex environment, the practice of off-label prescribing—utilizing FDA-approved medications for clinical indications, dosage regimens, or patient populations not explicitly specified in the official FDA-approved label—is a common, often life-saving reality […]